Emerging studies suggest Retatrutide , a dual activator targeting both the gut-brain axis and GIP , could offer a notable step forward for obesity treatment. Preliminary human investigations have indicated impressive losses in body tissue, conceivably outperforming current obesity therapies . Despite this, further evaluation is needed to thoroughly